Business · 25/10/20261 min read
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
Summary
The source item contains limited metadata.
Original source language: PR Newswire — Global News ReleasesOpen original release →